Exact Sciences Corp
NASDAQ:EXAS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
41.33
75.72
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one EXAS stock under the Base Case scenario is 41.93 USD. Compared to the current market price of 51.32 USD, Exact Sciences Corp is Overvalued by 18%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Exact Sciences Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for EXAS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Exact Sciences Corp. is a pioneering diagnostics company that focuses on the early detection and prevention of colorectal cancer, which is one of the deadliest cancers in the world. Founded in 1995 and based in Madison, Wisconsin, Exact Sciences made significant strides with its flagship product, Cologuard, the first non-invasive stool-based DNA test approved by the FDA for colorectal cancer screening. By combining advanced molecular biology and genetic testing, the company aims to enhance the efficiency and effectiveness of cancer screening processes, ultimately saving lives and reducing healthcare costs. This innovation has positioned Exact Sciences as a leader in preventive healthcare, ca...
Exact Sciences Corp. is a pioneering diagnostics company that focuses on the early detection and prevention of colorectal cancer, which is one of the deadliest cancers in the world. Founded in 1995 and based in Madison, Wisconsin, Exact Sciences made significant strides with its flagship product, Cologuard, the first non-invasive stool-based DNA test approved by the FDA for colorectal cancer screening. By combining advanced molecular biology and genetic testing, the company aims to enhance the efficiency and effectiveness of cancer screening processes, ultimately saving lives and reducing healthcare costs. This innovation has positioned Exact Sciences as a leader in preventive healthcare, catering to the growing demand for accessible and reliable cancer screening solutions in the U.S. and beyond.
As the company expands its product portfolio, it is also actively working on additional tests to detect other types of cancers and diseases, demonstrating its commitment to broadening its impact in the health sector. Exact Sciences has engaged in strategic collaborations and acquisitions to accelerate growth and innovation, including partnerships with large biopharmaceutical companies and healthcare providers. For investors, Exact Sciences presents a compelling opportunity—a company at the forefront of a vital healthcare sector, with proven products, a robust pipeline, and a mission that resonates with the increasing emphasis on preventive medicine. With strong revenue growth and a dedicated focus on research and development, Exact Sciences is poised for a future where early intervention and personalized care become the norm.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of cancer. The company primarily operates in two core business segments:
-
Colorectal Cancer Screening:
- One of Exact Sciences' flagship products is Cologuard, a non-invasive stool DNA test designed to detect colorectal cancer and pre-cancerous polyps. It provides a convenient alternative to traditional colonoscopy screening methods. The company has been actively promoting Cologuard for both screening and surveillance purposes, aiming to increase early detection rates and reduce mortality associated with colorectal cancer.
-
Oncology and Other Cancer Screening Tests:
- Exact Sciences has been expanding its portfolio to develop additional diagnostic tests for various cancers. This includes tests for other types of cancers beyond colorectal, such as breast and lung cancer. The company is engaged in research and development efforts to innovate and bring new cancer detection technologies to market.
Exact Sciences also focuses on generating evidence-based insights through numerous clinical studies and partnerships with healthcare providers. Their goal is to improve patient outcomes through better screening and early detection methods in oncology. This segment of their business is integral to their overall mission of reducing mortality rates associated with cancer through preventive measures.
Exact Sciences Corp, known for its innovations in cancer diagnostics, particularly for colorectal cancer screening through its Cologuard test, possesses several unique competitive advantages over its rivals:
-
Proprietary Technology: Exact Sciences has developed a non-invasive stool DNA test (Cologuard) that detects colorectal cancer and precancerous lesions. This proprietary technology is recognized for its accuracy and ease of use compared to traditional screening methods, giving it a significant edge.
-
Strong Clinical Evidence: The company has invested heavily in clinical trials, demonstrating the effectiveness and reliability of its products. The robust clinical data support the adoption of Cologuard, establishing trust among healthcare providers and patients.
-
Regulatory Approvals and Reimbursement: Exact Sciences has successfully navigated the regulatory landscape to obtain necessary approvals from the FDA and other agencies, along with securing favorable reimbursement policies. This established path makes it easier for healthcare providers to adopt its tests.
-
Brand Recognition and Trust: Being an early mover in the space of non-invasive colorectal cancer screening has allowed Exact Sciences to build strong brand recognition among both healthcare professionals and patients, fostering trust in its products.
-
Strong Partnerships: The company has established strategic partnerships with healthcare providers, payers, and influential organizations in the oncology space, enhancing its distribution channels and market reach.
-
Comprehensive Product Offering: Beyond Cologuard, Exact Sciences is expanding its product portfolio in cancer diagnostics, thus diversifying its revenue streams and reinforcing its market position.
-
Focus on Patient Compliance: The convenience of Cologuard encourages higher patient compliance compared to traditional methods (like colonoscopies). This advantage not only enhances the product's effectiveness but also helps drive market adoption.
-
Data Analytics and AI Integration: The company is increasingly leveraging data analytics and artificial intelligence to enhance its diagnostic capabilities and improve the accuracy of its tests, enabling it to stay ahead of competitors.
-
Commitment to Innovation: Exact Sciences has a culture of innovation that focuses on research and development to expand its test offerings and improve existing products, which helps in maintaining a competitive edge.
-
Market Positioning in a Growing Sector: With increasing awareness about early cancer detection and screening, the demand for non-invasive testing is likely to grow. Exact Sciences is well-positioned to capitalize on this trend.
These competitive advantages help Exact Sciences to not just retain its current market position but also to potentially expand its influence in the broader diagnostics and oncology markets.
Exact Sciences Corp, a molecular diagnostics company primarily focused on the early detection and prevention of cancer, faces several risks and challenges in the near future:
-
Regulatory Risks: The company operates in a heavily regulated environment. Changes in regulations, delayed approvals from the FDA for new tests, or increased scrutiny from regulatory bodies can impact their ability to bring new products to market.
-
Competition: The diagnostics market is highly competitive, with numerous players developing similar products. Increased competition could lead to pricing pressures and loss of market share.
-
Technological Challenges: Rapid advancements in technology require companies to continuously innovate. Failure to keep pace with new diagnostic technologies or to effectively integrate them into their offerings could hinder growth.
-
Reimbursement Issues: The coverage and reimbursement landscape is critical for diagnostic companies. Changes in healthcare policy, reductions in reimbursement rates, or denial of coverage for new tests can adversely affect revenues.
-
Market Adoption: Even if Exact Sciences develops innovative products, the adoption rate among healthcare providers and patients can be a challenge. Resistance to change or insufficient education about new tests can slow down market penetration.
-
Supply Chain Vulnerabilities: Disruptions in the supply chain can impact manufacturing capabilities and the delivery of products. Global issues, like those seen during pandemics, can exacerbate these risks.
-
Financial Risks: As a company focused on growth, Exact Sciences may face cash flow challenges, especially if it relies heavily on research and development. Additionally, fluctuations in stock prices can affect capital-raising efforts.
-
Public Perception and Trust: As a company involved in cancer diagnostics, any negative publicity or concerns about the accuracy of their tests can impact patient trust and market credibility.
-
Global Market Exposure: Expansion into international markets presents risks related to currency fluctuations, local regulations, and differing healthcare systems, which could complicate operations.
-
Strategic Partnerships: Relationships with healthcare providers, insurers, and other diagnostic firms are crucial. Changes in these partnerships or challenges in building new ones can limit growth opportunities.
Addressing these risks will be essential for Exact Sciences Corp to sustain its growth trajectory and maintain its position in the competitive landscape of cancer diagnostics.
Revenue & Expenses Breakdown
Exact Sciences Corp
Balance Sheet Decomposition
Exact Sciences Corp
Current Assets | 1.5B |
Cash & Short-Term Investments | 1B |
Receivables | 264.8m |
Other Current Assets | 247.2m |
Non-Current Assets | 5.2B |
PP&E | 834.4m |
Intangibles | 4.2B |
Other Non-Current Assets | 149.2m |
Current Liabilities | 723.7m |
Accounts Payable | 97.7m |
Accrued Liabilities | 341.2m |
Other Current Liabilities | 284.8m |
Non-Current Liabilities | 2.8B |
Long-Term Debt | 2.3B |
Other Non-Current Liabilities | 480.1m |
Earnings Waterfall
Exact Sciences Corp
Revenue
|
2.7B
USD
|
Cost of Revenue
|
-727.9m
USD
|
Gross Profit
|
2B
USD
|
Operating Expenses
|
-2.2B
USD
|
Operating Income
|
-208.9m
USD
|
Other Expenses
|
-5.1m
USD
|
Net Income
|
-214m
USD
|
Free Cash Flow Analysis
Exact Sciences Corp
USD | |
Free Cash Flow | USD |
EXAS Profitability Score
Profitability Due Diligence
Exact Sciences Corp's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Exact Sciences Corp's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
EXAS Solvency Score
Solvency Due Diligence
Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXAS Price Targets Summary
Exact Sciences Corp
According to Wall Street analysts, the average 1-year price target for EXAS is 81.05 USD with a low forecast of 61.61 USD and a high forecast of 105 USD.
Dividends
Current shareholder yield for EXAS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. The company is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.
Contact
IPO
Employees
Officers
The intrinsic value of one EXAS stock under the Base Case scenario is 41.93 USD.
Compared to the current market price of 51.32 USD, Exact Sciences Corp is Overvalued by 18%.